T. Rowe Price Associates
TNGX icon

T. Rowe Price Associates’s Tango Therapeutics TNGX Stock Holding History

T. Rowe Price Associates’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198M Buy
6,348,827
+5,459,427
+614% +$135M 0.02% 514
2026
Q1 		$18.6M Buy
889,400
+830,966
+1,422% +$11.6M ﹤0.01% 1064
2025
Q4 		$518K Buy
58,434
+17,765
+44% +$153K ﹤0.01% 2381
2025
Q3 		$343K Buy
40,669
+2,268
+6% +$15.3K ﹤0.01% 2538
2025
Q2 		$197K Buy
38,401
+16,149
+73% +$39.9K ﹤0.01% 2719
2025
Q1 		$31K Buy
22,252
+1,254
+6% +$3.08K ﹤0.01% 2982
2024
Q4 		$65K Buy
20,998
+4,813
+30% +$22.3K ﹤0.01% 2899
2024
Q3 		$125K Buy
16,185
+951
+6% +$9.07K ﹤0.01% 2778
2024
Q2 		$131K Buy
15,234
+2,463
+19% +$19K ﹤0.01% 2704
2024
Q1 		$102K Buy
12,771
+1,426
+13% +$15.3K ﹤0.01% 2782
2023
Q4 		$113K Buy
11,345
+1,129
+11% +$9.8K ﹤0.01% 2695
2023
Q3 		$116K Buy
+10,216
New +$62.3K ﹤0.01% 2633

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's TNGX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Tango Therapeutics (TNGX) stake by 614% in Q2 2026, buying an estimated $135M and bringing the position to 6,348,827 shares worth $198M. The position accounts for 0.02% of the portfolio, ranked #514.

T. Rowe Price Associates first reported a position in TNGX in Q3 2023 and has held it in 12 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • T. Rowe Price Associates held 6,348,827 shares of Tango Therapeutics worth $198M as of Q2 2026.
  • T. Rowe Price Associates bought 5,459,427 Tango Therapeutics shares in Q2 2026, an estimated $135M.
  • Tango Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #514 holding.
  • T. Rowe Price Associates first reported a position in Tango Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.